These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 27575023)

  • 1. Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis.
    Moran S; Martínez-Cardús A; Sayols S; Musulén E; Balañá C; Estival-Gonzalez A; Moutinho C; Heyn H; Diaz-Lagares A; de Moura MC; Stella GM; Comoglio PM; Ruiz-Miró M; Matias-Guiu X; Pazo-Cid R; Antón A; Lopez-Lopez R; Soler G; Longo F; Guerra I; Fernandez S; Assenov Y; Plass C; Morales R; Carles J; Bowtell D; Mileshkin L; Sia D; Tothill R; Tabernero J; Llovet JM; Esteller M
    Lancet Oncol; 2016 Oct; 17(10):1386-1395. PubMed ID: 27575023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic Profiling of CUP.
    Cancer Discov; 2016 Nov; 6(11):1203. PubMed ID: 27658716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and validation of a gene expression tumour classifier for cancer of unknown primary.
    Tothill RW; Shi F; Paiman L; Bedo J; Kowalczyk A; Mileshkin L; Buela E; Klupacs R; Bowtell D; Byron K
    Pathology; 2015 Jan; 47(1):7-12. PubMed ID: 25485653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An integrated tool for determining the primary origin site of metastatic tumours.
    Santos MTD; Souza BF; Cárcano FM; Vidal RO; Scapulatempo-Neto C; Viana CR; Carvalho AL
    J Clin Pathol; 2018 Jul; 71(7):584-593. PubMed ID: 29248889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient identification of miRNAs for classification of tumor origin.
    Søkilde R; Vincent M; Møller AK; Hansen A; Høiby PE; Blondal T; Nielsen BS; Daugaard G; Møller S; Litman T
    J Mol Diagn; 2014 Jan; 16(1):106-15. PubMed ID: 24211363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin.
    Tothill RW; Kowalczyk A; Rischin D; Bousioutas A; Haviv I; van Laar RK; Waring PM; Zalcberg J; Ward R; Biankin AV; Sutherland RL; Henshall SM; Fong K; Pollack JR; Bowtell DD; Holloway AJ
    Cancer Res; 2005 May; 65(10):4031-40. PubMed ID: 15899792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers.
    Kandimalla R; van Tilborg AA; Kompier LC; Stumpel DJ; Stam RW; Bangma CH; Zwarthoff EC
    Eur Urol; 2012 Jun; 61(6):1245-56. PubMed ID: 22284968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CUP-AI-Dx: A tool for inferring cancer tissue of origin and molecular subtype using RNA gene-expression data and artificial intelligence.
    Zhao Y; Pan Z; Namburi S; Pattison A; Posner A; Balachander S; Paisie CA; Reddi HV; Rueter J; Gill AJ; Fox S; Raghav KPS; Flynn WF; Tothill RW; Li S; Karuturi RKM; George J
    EBioMedicine; 2020 Nov; 61():103030. PubMed ID: 33039710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute.
    Hainsworth JD; Rubin MS; Spigel DR; Boccia RV; Raby S; Quinn R; Greco FA
    J Clin Oncol; 2013 Jan; 31(2):217-23. PubMed ID: 23032625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementation of a novel microarray-based diagnostic test for cancer of unknown primary.
    van Laar RK; Ma XJ; de Jong D; Wehkamp D; Floore AN; Warmoes MO; Simon I; Wang W; Erlander M; van't Veer LJ; Glas AM
    Int J Cancer; 2009 Sep; 125(6):1390-7. PubMed ID: 19536816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TOD-CUP: a gene expression rank-based majority vote algorithm for tissue origin diagnosis of cancers of unknown primary.
    Shen Y; Chu Q; Yin X; He Y; Bai P; Wang Y; Fang W; Timko MP; Fan L; Jiang W
    Brief Bioinform; 2021 Mar; 22(2):2106-2118. PubMed ID: 32266390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Head and neck cancer of unknown primary: unveiling primary tumor sites through machine learning on DNA methylation profiles.
    Stark L; Kasajima A; Stögbauer F; Schmidl B; Rinecker J; Holzmann K; Färber S; Pfarr N; Steiger K; Wollenberg B; Ruland J; Winter C; Wirth M
    Clin Epigenetics; 2024 Mar; 16(1):47. PubMed ID: 38528631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primary.
    Posner A; Prall OW; Sivakumaran T; Etemadamoghadam D; Thio N; Pattison A; Balachander S; Fisher K; Webb S; Wood C; DeFazio A; Wilcken N; Gao B; Karapetis CS; Singh M; Collins IM; Richardson G; Steer C; Warren M; Karanth N; Wright G; Williams S; George J; Hicks RJ; Boussioutas A; Gill AJ; Solomon BJ; Xu H; Fellowes A; Fox SB; Schofield P; Bowtell D; Mileshkin L; Tothill RW
    J Pathol; 2023 Jan; 259(1):81-92. PubMed ID: 36287571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation.
    Varadhachary GR; Talantov D; Raber MN; Meng C; Hess KR; Jatkoe T; Lenzi R; Spigel DR; Wang Y; Greco FA; Abbruzzese JL; Hainsworth JD
    J Clin Oncol; 2008 Sep; 26(27):4442-8. PubMed ID: 18802157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular classification of cancers of unknown primary site.
    Greco FA; Erlander MG
    Mol Diagn Ther; 2009 Dec; 13(6):367-73. PubMed ID: 19925034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.
    O'Byrne KJ; Gatzemeier U; Bondarenko I; Barrios C; Eschbach C; Martens UM; Hotko Y; Kortsik C; Paz-Ares L; Pereira JR; von Pawel J; Ramlau R; Roh JK; Yu CT; Stroh C; Celik I; Schueler A; Pirker R
    Lancet Oncol; 2011 Aug; 12(8):795-805. PubMed ID: 21782507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with
    Gröschel S; Bommer M; Hutter B; Budczies J; Bonekamp D; Heining C; Horak P; Fröhlich M; Uhrig S; Hübschmann D; Geörg C; Richter D; Pfarr N; Pfütze K; Wolf S; Schirmacher P; Jäger D; von Kalle C; Brors B; Glimm H; Weichert W; Stenzinger A; Fröhling S
    Cold Spring Harb Mol Case Stud; 2016 Nov; 2(6):a001180. PubMed ID: 27900363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of 18F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in the management of patients with carcinoma of unknown primary.
    Deonarine P; Han S; Poon FW; de Wet C
    Scott Med J; 2013 Aug; 58(3):154-62. PubMed ID: 23960054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue of origin prediction for cancer of unknown primary using a targeted methylation sequencing panel.
    Sun M; Xu B; Chen C; Zhu Y; Li X; Chen K
    Clin Epigenetics; 2024 Feb; 16(1):25. PubMed ID: 38336771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A molecular approach integrating genomic and DNA methylation profiling for tissue of origin identification in lung-specific cancer of unknown primary.
    Chen K; Zhang F; Yu X; Huang Z; Gong L; Xu Y; Li H; Yu S; Fan Y
    J Transl Med; 2022 Apr; 20(1):158. PubMed ID: 35382836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.